POLISCOPE
Back to feed
Part ofMedicare →
HR2408FEDERALIN_COMMITTEE
High Impact

Proposed Review Process for Medicare Drug Coverage Denials

Original title: Access to Innovative Treatments Act of 2023

December 17, 2024

MedicarePrescription DrugsHealthcare PolicyFederal Legislation

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced
Committee
Floor Vote
Passed
Signed

Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

Medicare beneficiaries may gain access to newer drugs that were previously excluded from coverage due to outdated or restrictive national coverage determinations.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medicare beneficiaries

The bill changes the process for determining whether specific drugs are covered under their insurance plan.

Prescription drug plan providers

These plans are prohibited from using certain national coverage determinations to deny payment for drugs.

What changed

Current stage: IN_COMMITTEE.

What's next

Floor Vote.

Summary

This bill creates a formal process for the federal government to review and potentially reverse Medicare coverage denials for specific drugs and biological products. It also prevents the government from applying outdated coverage restrictions to newly approved medications.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Frequently Asked Questions

What drugs are covered by this review process?
The process applies to drugs or approved by the FDA where Medicare coverage was denied or limited in a way that contradicts the drug's FDA approval.
Can the government keep denying coverage for a drug indefinitely?
No. The bill requires the Secretary to provide a final decision within 60 days of initiating a review, including summaries of public comments and the clinical evidence used.

Why It Matters

Medicare beneficiaries may gain access to newer drugs that were previously excluded from coverage due to outdated or restrictive national coverage determinations.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Sponsors

Connected Entities

organizationSecretary“The Secretary of Health and Human Services is responsible for initiating and con”Map →
organizationMedicare Coverage Advisory Committee“The committee's recommendations are considered during the review process.”Map →
personJoyce“Representative Joyce co-sponsored the bill.”Map →
otherSocial Security Act“The bill amends sections of the Social Security Act.”Map →
organizationU.S. Government Publishing Office“The bill is published by the U.S. Government Publishing Office.”Map →
personBarragan“Representative Barragan introduced the bill.”Map →

Analysis Score

0–100
  • Significance75
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz20
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record